Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Summary Muscle-invasive bladder cancers (MIBCs) are biologically heterogeneous and have widely variable clinical outcomes and responses to conventional chemotherapy. We discovered 3 molecular subtypes of MIBC that resembled established molecular subtypes of breast cancer. Basal MIBCs shared biomarkers with basal breast cancers and were characterized by p63 activation, squamous differentiation, and more aggressive disease at presentation. Luminal MIBCs contained features of active PPARγ and estrogen receptor (ER) transcription and were enriched with activating FGFR3 mutations and potentially FGFR inhibitor sensitivity. p53-like MIBCs were consistently resistant to neoadjuvant MVAC chemotherapy, and all chemoresistant tumors adopted a p53-like phenotype after therapy. Our observations have important implications for prognostication, the future clinical development of targeted agents, and disease management with conventional chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Cluster analysis and display of genome-wide expression patterns
Eisen, M. B., Spellman, P. T., Brown, P. O., & Botstein, D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14863 · Cited by 16,184
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, S. C., Tsykin, A., Farshid, G., Vadas, M. A., Khew-Goodall, Y., & Goodall, G. J. (2008) · Nature Cell Biology · doi:10.1038/ncb1722 · Cited by 3,863
Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype?
Peinado, H., Olmeda, D., & Cano, A. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2131 · Cited by 3,121 · cited 1×
“Although they expressed epithelial cytokeratins, basal tumors also contained ‘‘mesenchymal’’ biomarkers (i.e., TWIST1/2, SNAI2, ZEB2, and VIM;McConkey et al., 2010; Peinado et al., 2007; Figure S1B), as do basal breast cancers (Chaffer et al., 2013).”
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data
Dudoit, S., Fridlyand, J., & Speed, T. P. (2002) · Journal of the American Statistical Association · doi:10.1198/016214502753479248 · Cited by 2,672
Grossman, H. B., Natale, R. B., Tangen, C. M., Speights, V. O., Vogelzang, N. J., Trump, D. L., White, R. W. D., Sarosdy, M. F., Wood, D. P., Raghavan, D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022148 · Cited by 2,668
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
p53 Status and the Efficacy of Cancer Therapy in Vivo
Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., & Jacks, T. (1994) · Science · doi:10.1126/science.7973635 · Cited by 1,469
Cited by
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
Robertson, A. G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A. D., Hinoue, T., Laird, P. W., Hoadley, K. A., Akbani, R., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.007 · Cited by 2,443
Self-citationBalar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Self-citationUpdated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer
Alfred Witjes, J., Lebret, T., Compérat, E. M., Cowan, N. C., De Santis, M., Bruins, H. M., Hernández, V., Espinós, E. L., Dunn, J., Rouanne, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2016.06.020 · Cited by 1,476
Kamat, A. M., Hahn, N. M., Efstathiou, J. A., Lerner, S. P., Malmström, P.-U., Choi, W., Guo, C. C., Lotan, Y., & Kassouf, W. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30512-8 · Cited by 1,421
Self-citationA Consensus Molecular Classification of Muscle-invasive Bladder Cancer
Kamoun, A., de Reyniès, A., Allory, Y., Sjödahl, G., Robertson, A. G., Seiler, R., Hoadley, K. A., Groeneveld, C. S., Al-Ahmadie, H., Choi, W., et al. (2020) · European Urology · doi:10.1016/j.eururo.2019.09.006 · Cited by 1,359
Self-citationMolecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Knowles, M. A., & Hurst, C. D. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3817 · Cited by 1,247
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Patel, V. G., Oh, W. K., & Galsky, M. D. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21631 · Cited by 1,014
Attard, G., Parker, C., Eeles, R. A., Schröder, F., Tomlins, S. A., Tannock, I., Drake, C. G., & de Bono, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(14)61947-4 · Cited by 905
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
Damrauer, J. S., Hoadley, K. A., Chism, D. D., Fan, C., Tiganelli, C. J., Wobker, S. E., Yeh, J. J., Milowsky, M. I., Iyer, G., Parker, J. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318376111 · Cited by 877
Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer
Lee, S. H., Hu, W., Matulay, J. T., Silva, M. V., Owczarek, T. B., Kim, K., Chua, C. W., Barlow, L. J., Kandoth, C., Williams, A. B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.017 · Cited by 873
Sanli, O., Dobruch, J., Knowles, M. A., Burger, M., Alemozaffar, M., Nielsen, M. E., & Lotan, Y. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.22 · Cited by 814
Seiler, R., Ashab, H. A. D., Erho, N., van Rhijn, B. W. G., Winters, B., Douglas, J., Van Kessel, K. E., Fransen van de Putte, E. E., Sommerlad, M., Wang, N. Q., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.030 · Cited by 786
Self-citationAdvances in bladder cancer biology and therapy
Tran, L., Xiao, J.-F., Agarwal, N., Duex, J. E., & Theodorescu, D. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00313-1 · Cited by 735
Chen, Z., Zhou, L., Liu, L., Hou, Y., Xiong, M., Yang, Y., Hu, J., & Chen, K. (2020) · Nature Communications · doi:10.1038/s41467-020-18916-5 · Cited by 694
Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes
Dobruch, J., Daneshmand, S., Fisch, M., Lotan, Y., Noon, A. P., Resnick, M. J., Shariat, S. F., Zlotta, A. R., & Boorjian, S. A. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.037 · Cited by 673
Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2994 · Cited by 618
Alfred Witjes, J., Max Bruins, H., Carrión, A., Cathomas, R., Compérat, E., Efstathiou, J. A., Fietkau, R., Gakis, G., Lorch, A., Martini, A., et al. (2024) · European Urology · doi:10.1016/j.eururo.2023.08.016 · Cited by 648
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
Hedegaard, J., Lamy, P., Nordentoft, I., Algaba, F., Høyer, S., Ulhøi, B. P., Vang, S., Reinert, T., Hermann, G. G., Mogensen, K., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.004 · Cited by 639
Christensen, E., Birkenkamp-Demtröder, K., Sethi, H., Shchegrova, S., Salari, R., Nordentoft, I., Wu, H.-T., Knudsen, M., Lamy, P., Lindskrog, S. V., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02052 · Cited by 556
Plimack, E. R., Dunbrack, R. L., Brennan, T. A., Andrake, M. D., Zhou, Y., Serebriiskii, I. G., Slifker, M., Alpaugh, K., Dulaimi, E., Palma, N., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.009 · Cited by 519
Self-citationMutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications
Churi, C. R., Shroff, R., Wang, Y., Rashid, A., Kang, H. C., Weatherly, J., Zuo, M., Zinner, R., Hong, D., Meric-Bernstam, F., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115383 · Cited by 450
PPARgamma in Metabolism, Immunity, and Cancer: Unified and Diverse Mechanisms of Action
Hernandez-Quiles, M., Broekema, M. F., & Kalkhoven, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.624112 · Cited by 433
New insights into the role of EMT in tumor immune escape
Terry, S., Savagner, P., Ortiz‐Cuaran, S., Mahjoubi, L., Saintigny, P., Thiery, J., & Chouaib, S. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12093 · Cited by 414
“In bladder cancers, patients with tumors characterized by an Epi (luminal) phenotype had a better response rate while treated with anti-PD-L1 therapy compared to those harboring basal subtype (Rosenberg et al., 2016) expressing numerous Mes markers (Choi et al., 2014; Kamat et al., 2016).”
MethodHu, J., Yu, A., Othmane, B., Qiu, D., Li, H., Li, C., Liu, P., Ren, W., Chen, M., Gong, G., et al. (2021) · Theranostics · doi:10.7150/thno.53649 · Cited by 387
“such as CIT, Lund, MDA, TCGA, Baylor, UNC, and Consensus subtypes [19, 49-54].”
Rebouissou, S., Bernard-Pierrot, I., de Reyniès, A., Lepage, M.-L., Krucker, C., Chapeaublanc, E., Hérault, A., Kamoun, A., Caillault, A., Letouzé, E., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008970 · Cited by 386
Lindskrog, S. V., Prip, F., Lamy, P., Taber, A., Groeneveld, C. S., Birkenkamp-Demtröder, K., Jensen, J. B., Strandgaard, T., Nordentoft, I., Christensen, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22465-w · Cited by 378
Sjödahl, G., Eriksson, P., Liedberg, F., & Höglund, M. (2017) · The Journal of Pathology · doi:10.1002/path.4886 · Cited by 366
Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Sweis, R. F., Spranger, S., Bao, R., Paner, G. P., Stadler, W. M., Steinberg, G., & Gajewski, T. F. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0274 · Cited by 351
Dadhania, V., Zhang, M., Zhang, L., Bondaruk, J., Majewski, T., Siefker-Radtke, A., Guo, C. C., Dinney, C., Cogdell, D. E., Zhang, S., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.036 · Cited by 345
Self-citationEMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer
Wang, L., Saci, A., Szabo, P. M., Chasalow, S. D., Castillo-Martin, M., Domingo-Domenech, J., Siefker-Radtke, A., Sharma, P., Sfakianos, J. P., Gong, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05992-x · Cited by 313
Self-citationHurst, C. D., Alder, O., Platt, F. M., Droop, A., Stead, L. F., Burns, J. E., Burghel, G. J., Jain, S., Klimczak, L. J., Lindsay, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.005 · Cited by 311
Zhao, S. G., Chang, S. L., Erho, N., Yu, M., Lehrer, J., Alshalalfa, M., Speers, C., Cooperberg, M. R., Kim, W., Ryan, C. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0751 · Cited by 308
Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer
Choi, W., Czerniak, B., Ochoa, A., Su, X., Siefker-Radtke, A., Dinney, C., & McConkey, D. J. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.129 · Cited by 302
Self-citationTeo, M. Y., Bambury, R. M., Zabor, E. C., Jordan, E., Al-Ahmadie, H., Boyd, M. E., Bouvier, N., Mullane, S. A., Cha, E. K., Roper, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2520 · Cited by 280
McConkey, D. J., Choi, W., Shen, Y., Lee, I.-L., Porten, S., Matin, S. F., Kamat, A. M., Corn, P., Millikan, R. E., Dinney, C., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.08.034 · Cited by 277
Self-citationMolecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors
Tan, T. Z., Rouanne, M., Tan, K. T., Huang, R. Y.-J., & Thiery, J.-P. (2019) · European Urology · doi:10.1016/j.eururo.2018.08.027 · Cited by 277
Mouse and human urothelial cancer organoids: A tool for bladder cancer research
Mullenders, J., de Jongh, E., Brousali, A., Roosen, M., Blom, J. P. A., Begthel, H., Korving, J., Jonges, T., Kranenburg, O., Meijer, R., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803595116 · Cited by 277
Tumor-Derived Cell Lines as Molecular Models of Cancer Pharmacogenomics
Goodspeed, A., Heiser, L. M., Gray, J. W., & Costello, J. C. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0189 · Cited by 276
Martinelli, P., Carrillo-de Santa Pau, E., Cox, T., Sainz, B., Dusetti, N., Greenhalf, W., Rinaldi, L., Costello, E., Ghaneh, P., Malats, N., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311256 · Cited by 269
Creation of bladder assembloids mimicking tissue regeneration and cancer
Kim, E., Choi, S., Kang, B., Kong, J., Kim, Y., Yoon, W. H., Lee, H.-R., Kim, S., Kim, H.-M., Lee, H., et al. (2020) · Nature · doi:10.1038/s41586-020-3034-x · Cited by 260
Self-citationPitroda, S. P., Khodarev, N. N., Huang, L., Uppal, A., Wightman, S. C., Ganai, S., Joseph, N., Pitt, J., Brown, M., Forde, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04278-6 · Cited by 254
Kamat, A. M., Flaig, T. W., Grossman, H. B., Konety, B., Lamm, D., O'Donnell, M. A., Uchio, E., Efstathiou, J. A., & Taylor, J. A. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.58 · Cited by 252
SASP: Tumor Suppressor or Promoter? Yes!
Rao, S. G., & Jackson, J. G. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.001 · Cited by 206
(2021) · doi:10.1158/1078-0432.ccr-20-4175 · Cited by 172
MOGSA: Integrative Single Sample Gene-set Analysis of Multiple Omics Data
(2019) · doi:10.1074/mcp.tir118.001251 · Cited by 78
Li, H., Chen, J., Li, Z., Chen, M., Ou, Z., Mo, M., Wang, R., Tong, S., Liu, P., Cai, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202300110 · Cited by 49
Koll, F. J., Banek, S., Kluth, L., Köllermann, J., Bankov, K., Chun, F. K.-H., Wild, P. J., Weigert, A., & Reis, H. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03949-3 · Cited by 47
Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?
Azevedo, R., Peixoto, A., Gaiteiro, C., Fernandes, E., Neves, M., Lima, L., Santos, L. L., & Ferreira, J. A. (2017) · Oncotarget · doi:10.18632/oncotarget.19433 · Cited by 39
“Therefore, the field must now focus on large scale multicentric translational studies integrating glycomics data with novel molecular findings, including recently proposed models for bladder cancer risk-stratification [261-263].”
BackgroundZhang, X., Wang, J., Lu, J., Su, L., Wang, C., Huang, Y., Zhang, X., & Zhu, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.689626 · Cited by 24
Chu, C. E., Sjöström, M., Egusa, E. A., Gibb, E. A., Badura, M. L., Zhu, J., Koshkin, V. S., Stohr, B. A., Meng, M. V., Pruthi, R. S., et al. (2023) · doi:10.1158/1078-0432.c.6530730
Self-citationChu, C. E., Sjöström, M., Egusa, E. A., Gibb, E. A., Badura, M. L., Zhu, J., Koshkin, V. S., Stohr, B. A., Meng, M. V., Pruthi, R. S., et al. (2023) · doi:10.1158/1078-0432.c.6530730.v1
Self-citation
Metadata
- Authors
- Choi, W., Porten, S., Kim, S., Willis, D., Plimack, E. R., Hoffman-Censits, J., Roth, B., Cheng, T., Tran, M., Lee, I.-L., Melquist, J., Bondaruk, J., Majewski, T., Zhang, S., Pretzsch, S., Baggerly, K., Siefker-Radtke, A., Czerniak, B., Dinney, C. P. N., & McConkey, D. J.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2014-02
- Volume
- 25
- Issue
- 2
- Pages
- 152-165
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2033775272
- Cited by
- 1,716
- References
- 40
- FWCI
- 120.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.